OBJECTIVE: The increasing population of human immunodeficiency virus (HIV)-infected elderly patients results in a higher number of comorbidities and greater incidence of polypharmacy in addition to antiretroviral therapy (ART). The aim of this study is to describe the use of concomitant medication in older HIV-infected patients and to compare it with older general population. METHODS: The study included HIV-positive outpatients (>49 years) who received ART in 2011. Co-medication dispensed by pharmacies in that year was collected. Defined daily dose (DDD) for each drug was calculated by patient. A comparison was made between the use of co-medication among men between 50 and 64 years old in general population against the HIV-infected population. RESULTS: The study was based on 118 patients (77% men), of which 82% took at least one co-medication and 58% at least five. The commonest co-medications used by HIV-positive patients were antibiotics (44%); analgesics (44%); anti-inflammatories (39%); antacids (38%); and psycholeptics (38%). The medicines used for the greatest number of days per HIV-positive patient were those related to the renin-angiotensin system; anti-diabetics; lipid modifying agents; antithrombotics; and calcium channel blockers. In comparison with the general male population, a higher proportion of HIV-infected patients used antibiotics (42 vs 30%, P = 0.018), antiepileptics (16 vs 5%, P = 0.000), psycholeptics (35 vs 17%, P = 0.000) and COPD medications (14 vs 7%, P = 0.008). The duration of antibiotics and psycholeptic use in HIV-infected patients was longer compared to the general population (P < 0.05). CONCLUSIONS: Older HIV-positive patients frequently take a higher number of co-medication, which increases the risk of adverse events, interactions with other medication, and may lead to poorer treatment adherence.
OBJECTIVE: The increasing population of human immunodeficiency virus (HIV)-infected elderly patients results in a higher number of comorbidities and greater incidence of polypharmacy in addition to antiretroviral therapy (ART). The aim of this study is to describe the use of concomitant medication in older HIV-infectedpatients and to compare it with older general population. METHODS: The study included HIV-positive outpatients (>49 years) who received ART in 2011. Co-medication dispensed by pharmacies in that year was collected. Defined daily dose (DDD) for each drug was calculated by patient. A comparison was made between the use of co-medication among men between 50 and 64 years old in general population against the HIV-infected population. RESULTS: The study was based on 118 patients (77% men), of which 82% took at least one co-medication and 58% at least five. The commonest co-medications used by HIV-positive patients were antibiotics (44%); analgesics (44%); anti-inflammatories (39%); antacids (38%); and psycholeptics (38%). The medicines used for the greatest number of days per HIV-positive patient were those related to the renin-angiotensin system; anti-diabetics; lipid modifying agents; antithrombotics; and calcium channel blockers. In comparison with the general male population, a higher proportion of HIV-infectedpatients used antibiotics (42 vs 30%, P = 0.018), antiepileptics (16 vs 5%, P = 0.000), psycholeptics (35 vs 17%, P = 0.000) and COPD medications (14 vs 7%, P = 0.008). The duration of antibiotics and psycholeptic use in HIV-infectedpatients was longer compared to the general population (P < 0.05). CONCLUSIONS: Older HIV-positive patients frequently take a higher number of co-medication, which increases the risk of adverse events, interactions with other medication, and may lead to poorer treatment adherence.
Entities:
Keywords:
Aging,; Antiretroviral therapy,; Dosing; Drug utilization,; HIV/AIDS,
Authors: Leah H Rubin; Ava G Neijna; Qiuhu Shi; Donald R Hoover; Bani Tamraz; Kathryn Anastos; Andrew Edmonds; Margaret A Fischl; Deborah Gustafson; Pauline M Maki; Daniel Merenstein; Anandi N Sheth; Gayle Springer; David Vance; Kathleen M Weber; Anjali Sharma Journal: AIDS Res Hum Retroviruses Date: 2022-04-26 Impact factor: 1.723
Authors: Kendra K Radtke; Peter Bacchetti; Kathryn Anastos; Daniel Merenstein; Howard Crystal; Roksana Karim; Kathleen M Weber; Andrew Edmonds; Anandi N Sheth; Margaret A Fischl; David Vance; Ruth M Greenblatt; Leah H Rubin Journal: J Acquir Immune Defic Syndr Date: 2018-06-01 Impact factor: 3.731
Authors: Krista J Siefried; Limin Mao; Lucette A Cysique; John Rule; Michelle L Giles; Don E Smith; James McMahon; Tim R Read; Catriona Ooi; Ban K Tee; Mark Bloch; John de Wit; Andrew Carr Journal: AIDS Date: 2018-01-02 Impact factor: 4.177
Authors: Mercedes Gimeno-Gracia; María José Crusells-Canales; Francisco Javier Armesto-Gómez; Vicente Compaired-Turlán; María José Rabanaque-Hernández Journal: Clin Interv Aging Date: 2016-08-26 Impact factor: 4.458
Authors: Gaelen P Adam; Mengyang Di; Susan Cu-Uvin; Christopher Halladay; Bryant T Smith; Suchitra Iyer; Thomas A Trikalinos Journal: Syst Rev Date: 2018-02-02